Business, energy, technology, markets and global industry news from Business News Today

ASGCT

PharmaDeviceNews ASGCT
Representative image of circular RNA-based in vivo CAR-T research in a biotechnology laboratory, highlighting Therorna’s TI-0032 program and the growing push to make cell therapy more scalable for autoimmune disease treatment.
Pharma & Biotech

Could Therorna’s circRNA in vivo CAR-T platform change autoimmune disease treatment?

CAR-T is powerful but hard to scale. Therorna’s circRNA platform tests whether in vivo engineering can move the field beyond bespoke therapy.

Read More
Representative image: Ensoma’s EN-374 clinical safety data highlight the growing promise of in vivo hematopoietic stem cell engineering for X-linked chronic granulomatous disease, as gene therapy developers test whether one-time treatments can move beyond complex ex vivo manufacturing and into scalable clinical use.
Pharma & Biotech

Ensoma’s EN-374 safety data open a new test for in vivo HSC engineering

In vivo gene therapy has reached human HSC engineering. Ensoma’s EN-374 safety data raise a bigger question: can durability follow?

Read More